glp-1/glucagon dual receptor agonist Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research The Effects of Dual GLP-1/GIP
Description
& Kumar, R
Danuglipron Danuglipron is a small-molecule GLP-1 receptor agonist, formerly under development by Pfizer [1] that, in an oral formulation, was under investigation as a therapy for diabetes mellitus
The threat is real but manageable
This means researchers face a genuine cost-benefit analysis when choosing their target maintenance dose
B.DiamantM.FerranniniE.NauckM.et al (2015)
